KNTE Insider Transactions
| Transaction Date (SEC Report ) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2023-03-01 | Williams Richard Thomas | officer: Chief Medical Officer | 67,295 | F-InKind | D | 638 | 5.21 | 3,323.98 |
| 2023-03-01 | DeSimone Jill | director | 50,000 | A-Award | A | 50,000 | 5.21 | 260,500.00 |
| 2023-03-01 | Krishnamohan Neha | officer: Chief Financial Officer | 67,378 | F-InKind | D | 1,721 | 5.21 | 8,966.41 |
| 2023-03-01 | Meltz Mark A | officer: COO General Counsel Secretary | 27,286 | F-InKind | D | 638 | 5.21 | 3,323.98 |
| 2023-02-17 | ORBIMED ADVISORS LLC | director, 10 percent owner | 550,000 | A-Award | A | 550,000 | 0.00 | 0.00 |
| 2023-02-17 | GORDON CARL L | director, 10 percent owner | 550,000 | A-Award | A | 550,000 | 0.00 | 0.00 |
| 2023-02-17 | Foresite Capital Management IV, LLC | 10 percent owner | 1,975,001 | J-Other | A | 1,100,000 | 0.00 | 0.00 |
| 2023-02-17 | Tananbaum James B. | director, 10 percent owner | 1,975,001 | J-Other | A | 1,100,000 | 0.00 | 0.00 |
| 2023-02-10 | Farzan Nima | director, officer: Chief Executive Officer | 750,000 | A-Award | A | 750,000 | 6.78 | 5,085,000.00 |
| 2023-02-10 | Farzan Nima | director, officer: Chief Executive Officer | 215,000 | A-Award | A | 750,000 | 6.78 | 5,085,000.00 |
| 2023-02-10 | Williams Richard Thomas | officer: Chief Medical Officer | 215,000 | A-Award | A | 215,000 | 6.78 | 1,457,700.00 |
| 2023-02-10 | Meltz Mark A | officer: COO General Counsel Secretary | 215,000 | A-Award | A | 215,000 | 6.78 | 1,457,700.00 |
| 2023-02-10 | Krishnamohan Neha | officer: Chief Financial Officer | 215,000 | A-Award | A | 215,000 | 6.78 | 1,457,700.00 |
| 2022-12-01 | Meltz Mark A | officer: COO General Counsel Secretary | 27,924 | F-InKind | D | 541 | 7.75 | 4,192.75 |
| 2022-12-01 | Krishnamohan Neha | officer: Chief Financial Officer | 69,099 | F-InKind | D | 1,459 | 7.75 | 11,307.25 |
| 2022-12-01 | Williams Richard Thomas | officer: Chief Medical Officer | 67,933 | F-InKind | D | 541 | 7.75 | 4,192.75 |
| 2022-09-01 | Meltz Mark A | officer: COO General Counsel Secretary | 28,465 | A-Award | A | 25,000 | 0.00 | 0.00 |
| 2022-09-01 | Krishnamohan Neha | officer: Chief Financial Officer | 69,015 | A-Award | A | 67,500 | 0.00 | 0.00 |
| 2022-09-01 | Williams Richard Thomas | officer: Chief Medical Officer | 68,474 | A-Award | A | 25,000 | 0.00 | 0.00 |
| 2022-06-13 | Epperly Melissa B, | director | 20,250 | A-Award | A | 20,250 | 8.38 | 169,695.00 |
| 2022-06-13 | Smaldone Alsup Laurie | director | 20,250 | A-Award | A | 20,250 | 8.38 | 169,695.00 |
| 2022-06-13 | Rome Michael E | director | 20,250 | A-Award | A | 20,250 | 8.38 | 169,695.00 |
| 2022-06-13 | GORDON CARL L | director | 20,250 | A-Award | A | 20,250 | 8.38 | 169,695.00 |
| 2022-06-13 | Tananbaum James B. | director | 20,250 | A-Award | A | 20,250 | 8.38 | 169,695.00 |
| 2022-06-13 | MITCHELL DEAN J | director | 20,250 | A-Award | A | 20,250 | 8.38 | 169,695.00 |
| 2022-06-13 | Flaherty Keith T. | director | 20,250 | A-Award | A | 20,250 | 8.38 | 169,695.00 |
| 2022-06-13 | Sabzevari Helen | director | 20,250 | A-Award | A | 20,250 | 8.38 | 169,695.00 |
| 2022-03-14 | Williams Richard Thomas | officer: Chief Medical Officer | 42,333 | P-Purchase | A | 25,000 | 8.37 | 209,250.00 |
| 2022-03-11 | Williams Richard Thomas | officer: Chief Medical Officer | 17,333 | P-Purchase | A | 15,000 | 8.64 | 129,600.00 |
| 2022-02-15 | GORDON CARL L | director | 3,509,030 | P-Purchase | A | 9,000 | 9.96 | 89,640.00 |
| 2022-02-15 | ORBIMED ADVISORS LLC | director | 3,509,030 | P-Purchase | A | 9,000 | 9.96 | 89,640.00 |
| 2022-02-14 | GORDON CARL L | director | 3,500,030 | P-Purchase | A | 10,000 | 9.89 | 98,900.00 |
| 2022-02-14 | GORDON CARL L | director | 3,490,030 | P-Purchase | A | 20,700 | 9.98 | 206,586.00 |
| 2022-02-14 | ORBIMED ADVISORS LLC | director | 3,500,030 | P-Purchase | A | 10,000 | 9.89 | 98,900.00 |
| 2022-02-14 | ORBIMED ADVISORS LLC | director | 3,490,030 | P-Purchase | A | 20,700 | 9.98 | 206,586.00 |
| 2022-02-11 | GORDON CARL L | director | 3,469,330 | P-Purchase | A | 156,000 | 10.22 | 1,594,320.00 |
| 2022-02-11 | Williams Richard Thomas | officer: Chief Medical Officer | 135,000 | A-Award | A | 135,000 | 10.03 | 1,354,050.00 |
| 2022-02-11 | Farzan Nima | director, officer: Chief Executive Officer | 400,000 | A-Award | A | 400,000 | 10.03 | 4,012,000.00 |
| 2022-02-11 | Krishnamohan Neha | officer: Chief Financial Officer | 185,000 | A-Award | A | 185,000 | 10.03 | 1,855,550.00 |
| 2022-02-11 | Meltz Mark A | officer: COO General Counsel Treasurer | 135,000 | A-Award | A | 135,000 | 10.03 | 1,354,050.00 |
| 2022-02-11 | ORBIMED ADVISORS LLC | director | 3,469,330 | P-Purchase | A | 156,000 | 10.22 | 1,594,320.00 |
| 2021-06-24 | Sabzevari Helen | director | 40,501 | A-Award | A | 40,501 | 24.38 | 987,414.38 |
| 2021-06-11 | Epperly Melissa B, | director | 20,250 | A-Award | A | 20,250 | 24.46 | 495,315.00 |
| 2021-06-11 | Flaherty Keith T. | director | 20,250 | A-Award | A | 20,250 | 24.46 | 495,315.00 |
| 2021-06-11 | Smaldone Alsup Laurie | director | 20,250 | A-Award | A | 20,250 | 24.46 | 495,315.00 |
| 2021-06-11 | MITCHELL DEAN J | director | 20,250 | A-Award | A | 20,250 | 24.46 | 495,315.00 |
| 2021-06-07 | Krishnamohan Neha | officer: Chief Financial Officer | 270,000 | A-Award | A | 270,000 | 23.26 | 6,280,200.00 |
| 2021-02-12 | Murphy Eric Anthony | officer: Chief Scientific Officer | 60,000 | A-Award | A | 60,000 | 35.38 | 2,122,800.00 |
| 2021-02-12 | Williams Richard Thomas | officer: Chief Medical Officer | 100,000 | A-Award | A | 100,000 | 35.38 | 3,538,000.00 |
| 2021-02-12 | Farzan Nima | director, officer: Chief Executive Officer | 275,000 | A-Award | A | 275,000 | 35.38 | 9,729,500.00 |
| 2021-02-12 | Meltz Mark A | officer: COO General Counsel Treasurer | 100,000 | A-Award | A | 100,000 | 35.38 | 3,538,000.00 |
| 2020-12-07 | ORBIMED ADVISORS LLC | director, 10 percent owner | 0 | C-Conversion | D | 24,555 | 0.00 | 0.00 |
| 2020-12-07 | ORBIMED ADVISORS LLC | director, 10 percent owner | 0 | C-Conversion | D | 24,555 | 0.00 | 0.00 |
| 2020-12-07 | ORBIMED ADVISORS LLC | director, 10 percent owner | 0 | C-Conversion | D | 24,555 | 0.00 | 0.00 |
| 2020-12-07 | ORBIMED ADVISORS LLC | director, 10 percent owner | 84,599 | C-Conversion | A | 24,637 | 0.00 | 0.00 |
| 2020-12-07 | ORBIMED ADVISORS LLC | director, 10 percent owner | 59,962 | C-Conversion | A | 9,461 | 0.00 | 0.00 |
| 2020-12-07 | ORBIMED ADVISORS LLC | director, 10 percent owner | 543,494 | C-Conversion | A | 243,494 | 0.00 | 0.00 |
| 2020-12-07 | Foresite Capital Management IV, LLC | 10 percent owner | 0 | C-Conversion | D | 48,376 | 0.00 | 0.00 |
| 2020-12-07 | Foresite Capital Management IV, LLC | 10 percent owner | 0 | C-Conversion | D | 48,376 | 0.00 | 0.00 |
| 2020-12-07 | Foresite Capital Management IV, LLC | 10 percent owner | 0 | C-Conversion | D | 48,376 | 0.00 | 0.00 |
| 2020-12-07 | Foresite Capital Management IV, LLC | 10 percent owner | 291,667 | C-Conversion | A | 166,667 | 0.00 | 0.00 |
| 2020-12-07 | Foresite Capital Management IV, LLC | 10 percent owner | 9,671,643 | C-Conversion | A | 9,171,643 | 0.00 | 0.00 |
| 2020-12-07 | GORDON CARL L | 543,494 | C-Conversion | A | 243,494 | 0.00 | 0.00 | |
| 2020-12-07 | GORDON CARL L | 0 | C-Conversion | D | 243,494 | 0.00 | 0.00 | |
| 2020-12-07 | GORDON CARL L | 3,194,536 | C-Conversion | A | 2,651,042 | 0.00 | 0.00 | |
| 2020-12-07 | GORDON CARL L | 3,313,330 | C-Conversion | A | 118,794 | 0.00 | 0.00 | |
| 2020-12-07 | GORDON CARL L | 50,501 | C-Conversion | A | 50,501 | 0.00 | 0.00 | |
| 2020-12-07 | GORDON CARL L | 59,962 | C-Conversion | A | 9,461 | 0.00 | 0.00 | |
| 2020-12-07 | GORDON CARL L | 84,599 | C-Conversion | A | 24,637 | 0.00 | 0.00 | |
| 2020-12-07 | Foresite Capital Management IV, LLC | 10 percent owner | 875,001 | C-Conversion | A | 500,001 | 0.00 | 0.00 |
| 2020-12-07 | ORBIMED ADVISORS LLC | director, 10 percent owner | 3,194,536 | C-Conversion | A | 2,651,042 | 0.00 | 0.00 |
| 2020-12-07 | ORBIMED ADVISORS LLC | director, 10 percent owner | 3,313,330 | C-Conversion | A | 118,794 | 0.00 | 0.00 |
| 2020-12-07 | ORBIMED ADVISORS LLC | director, 10 percent owner | 50,501 | C-Conversion | A | 50,501 | 0.00 | 0.00 |
| 2020-12-07 | Tananbaum James B. | 291,667 | C-Conversion | A | 166,667 | 0.00 | 0.00 | |
| 2020-12-07 | Tananbaum James B. | 0 | C-Conversion | D | 6,347,893 | 0.00 | 0.00 | |
| 2020-12-07 | Tananbaum James B. | 875,001 | C-Conversion | A | 500,001 | 0.00 | 0.00 | |
| 2020-12-07 | Tananbaum James B. | 9,671,643 | C-Conversion | A | 9,171,643 | 0.00 | 0.00 | |
| 2020-12-03 | Tananbaum James B. | 375,000 | P-Purchase | A | 375,000 | 20.00 | 7,500,000.00 | |
| 2020-12-03 | Tananbaum James B. | 125,000 | P-Purchase | A | 125,000 | 20.00 | 2,500,000.00 | |
| 2020-12-03 | Tananbaum James B. | 500,000 | P-Purchase | A | 500,000 | 20.00 | 10,000,000.00 | |
| 2020-12-03 | Foresite Capital Management IV, LLC | 500,000 | A-Award | A | 500,000 | 0.00 | 0.00 | |
| 2020-12-03 | Foresite Capital Management IV, LLC | 375,000 | A-Award | A | 375,000 | 0.00 | 0.00 | |
| 2020-12-03 | Foresite Capital Management IV, LLC | 125,000 | A-Award | A | 125,000 | 0.00 | 0.00 | |
| 2020-12-02 | Rome Michael E | 40,501 | A-Award | A | 40,501 | 20.00 | 810,020.00 | |
| 2020-12-02 | ORBIMED ADVISORS LLC | 300,000 | P-Purchase | A | 300,000 | 20.00 | 6,000,000.00 | |
| 2020-12-02 | ORBIMED ADVISORS LLC | 450,000 | P-Purchase | A | 450,000 | 20.00 | 9,000,000.00 | |
| 2020-12-02 | Tananbaum James B. | 40,501 | A-Award | A | 40,501 | 0.00 | 0.00 | |
| 2020-12-02 | GORDON CARL L | 300,000 | P-Purchase | A | 300,000 | 20.00 | 6,000,000.00 | |
| 2020-12-02 | GORDON CARL L | 40,501 | A-Award | A | 40,501 | 20.00 | 810,020.00 | |
| 2020-12-02 | GORDON CARL L | 450,000 | P-Purchase | A | 450,000 | 20.00 | 9,000,000.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Group doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Group or anyone involved with Discounting Cash Flows Group will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.